The FY2023 (Dec) proxy of Natera names 24 peer companies for pay. Among Natera and these peers, CEO pay was the highest of 2 and total shareholder return was the lowest of 2.
1st highest of 2in Natera and its pay peers, FY2023 (Dec) by CEO pay:
$7.8M$12.7M
2nd highest of 2in Natera and its pay peers, FY2023 (Dec) by total shareholder return:
$186$235
Pay peer group, FY2023 (Dec) proxy
| Qualys | ||
| 10x Genomics, Inc. | Not disclosed | Not disclosed |
| Abiomed, Inc. | Not disclosed | Not disclosed |
| BIO-TECHNE | Not disclosed | Not disclosed |
| CareDx, Inc. | Not disclosed | Not disclosed |
| Exact Sciences Corporation | Not disclosed | Not disclosed |
| Exelixis, Inc. | Not disclosed | Not disclosed |
| Glaukos Corporation | Not disclosed | Not disclosed |
| Guardant Health, Inc. | Not disclosed | Not disclosed |
| Ionis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Masimo Corporation | Not disclosed | Not disclosed |
| Myriad Genetics, Inc. | Not disclosed | Not disclosed |
| NeoGenomics, Inc. | Not disclosed | Not disclosed |
| Neurocrine Biosciences, Inc. | Not disclosed | Not disclosed |
| Nevro Corp. | Not disclosed | Not disclosed |
| New Relic, Inc. | Not disclosed | Not disclosed |
| NovoCure Ltd. | Not disclosed | Not disclosed |
| PTC Therapeutics, Inc. | Not disclosed | Not disclosed |
| Penumbra, Inc. | Not disclosed | Not disclosed |
| Quidel Corporation | Not disclosed | Not disclosed |
| Repligen Corporation | Not disclosed | Not disclosed |
| Ultragenyx Pharmaceutical, Inc. | Not disclosed | Not disclosed |
| Veracyte, Inc. | Not disclosed | Not disclosed |
| iRhythm Technologies, Inc. | Not disclosed | Not disclosed |
24 companies
Changes by year
FY2025 (Dec) proxy
- AddedAlnylam Pharmaceuticalspay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- AddedBeiGenepay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- AddedIlluminapay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- AddedIncytepay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- AddedInsuletpay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- AddedRevvitypay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- Removed10x Genomics, iRhythmpay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- RemovedMyriad Geneticspay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- RemovedNeoGenomicspay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- RemovedNovoCurepay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- RemovedPTC Therapeuticspay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- RemovedQuidelOrthopay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
- RemovedUltragenyxpay peer groupSpecifically, the committee removed New Relic (acquired), and 10x Genomics, iRhythm, Myriad Genetics, NeoGenomics, NovoCure, PTC Therapeutics, QuidelOrtho and Ultragenyx, which no longer met the criteria, and added Alnylam Pharmaceuticals, BeiGene, Illumina, Incyte, Insulet and Revvity
'%20fill='none'%20fill-rule='evenodd'%3e%3cpath%20d='M7.497%2029.085s2.985.806%203.69-.538c1.658-3.153-3.086-13.225-3.086-13.225s5.502%2013.038%2011.82%2019.07c3.464%203.305%207.438%203.503%2010.166%201.999%205.572-3.077%2013.026-18.379%2013.854-19.916.829-1.539-5.422%2013.84-7.605%2017.3-2.183%203.462-4.066%207.458-11.143%207.69-8.462.275-17.696-12.38-17.696-12.38'%20fill='%230F9BD7'/%3e%3cg%20transform='translate(0%2016.123)'%3e%3cmask%20id='iz0ij2keyb'%20fill='%23fff'%3e%3cuse%20xlink:href='%23bbe95veu1a'/%3e%3c/mask%3e%3cpath%20d='M0%203.043C0%201.363%201.333%200%202.98%200c1.645%200%202.977%201.363%202.977%203.043%200%201.68-1.332%203.042-2.977%203.042C1.333%206.085%200%204.722%200%203.043'%20fill='%23ACD5F1'%20mask='url(%23iz0ij2keyb)'/%3e%3c/g%3e%3cg%20transform='translate(7.873)'%3e%3cmask%20id='vrpx36r1md'%20fill='%23fff'%3e%3cuse%20xlink:href='%23bwovqcdwic'/%3e%3c/mask%3e%3cpath%20d='M13.028%204.171s2.184-.77%202.484-.384c.63.804.528%201.614-1.206%203.614-1.73%201.999-6.7%207.304-6.7%207.304s10.186-9.316%2013.025-8.38c2.336.768%201.358%204.152.98%205.381-.377%201.231-4.97%2013.919-21.61%2040.292-.182.29%2024.462-29.757%2025.525-42.52.903-10.843-4.292-9.46-4.669-9.38-4.411.9-7.83%204.073-7.83%204.073'%20fill='%231A3967'%20mask='url(%23vrpx36r1md)'/%3e%3c/g%3e%3cpath%20d='M64.023%2029.175%2058.52%2015.877l-5.502%2013.298h11.005zm-5.964-17.374h.923L71.5%2041.356h-2.437l-4.243-10.209H52.22l-4.242%2010.21h-2.436L58.06%2011.8z'%20fill='%231A3967'/%3e%3cmask%20id='7uez1t42pf'%20fill='%23fff'%3e%3cuse%20xlink:href='%23z9efbhhede'/%3e%3c/mask%3e%3cpath%20fill='%231A3967'%20mask='url(%237uez1t42pf)'%20d='M75.616%2041.356h2.142V12.06h-2.142zM83.977%2022.011h2.1V25.1c1.806-2.275%203.948-3.433%206.551-3.433%204.285%200%206.722%202.832%206.722%207.893v11.798h-2.1V30.59c0-4.634-1.554-6.949-4.831-6.949-2.604%200-4.748%201.374-6.343%204.074v13.643h-2.1V22.01zM102.625%2022.011h2.352L111.7%2035.18l6.3-13.168h2.184L106.24%2051.095h-2.142l6.467-13.513zM123.46%2041.356h2.144V12.06h-2.145zM141.06%2031.404c-5.712.087-8.863%202.318-8.863%205.32%200%201.974%201.387%203.217%203.698%203.217%201.638%200%203.276-.857%205.166-2.487v-6.05zm-5.755%2010.38c-3.148%200-5.25-2.058-5.25-4.975%200-4.203%203.78-6.82%2011.006-7.12v-2.058c0-2.875-1.262-4.161-4.242-4.161-1.933%200-3.74.815-5.799%202.359v-2.103c2.06-1.415%203.992-2.144%205.965-2.144%204.454%200%206.177%202.06%206.177%206.562v10.124c0%20.856.21%201.245.672%201.245.587%200%201.133-.602%202.14-1.501v1.972c-1.216%201.159-2.266%201.76-3.066%201.76-1.218%200-1.723-.688-1.804-2.276-1.975%201.546-3.699%202.317-5.799%202.317zM149.335%2022.011h2.102V25.1c1.722-2.275%203.78-3.433%206.299-3.433%202.815%200%204.58%201.158%205.881%203.947%202.059-2.66%204.16-3.947%206.806-3.947%204.117%200%206.468%202.832%206.468%207.893v11.798h-2.142V30.59c0-4.634-1.47-6.949-4.579-6.949-2.478%200-4.537%201.374-6.006%204.074v13.643h-2.1V30.59c0-4.634-1.513-6.949-4.621-6.949-2.48%200-4.494%201.374-6.006%204.074v13.643h-2.102V22.01zM179.884%2019.427v1.083h.569c.602%200%20.86-.113.86-.558%200-.37-.285-.525-.86-.525h-.569zm1.826.539c0%20.403-.264.708-.687.757l.645%201.362h-.446l-.616-1.305h-.722v1.305h-.388v-2.928h1.034c.789%200%201.18.241%201.18.809zm.33-.916a2.192%202.192%200%200%200-1.587-.67c-.603%200-1.152.232-1.56.656a2.335%202.335%200%200%200-.666%201.622c0%20.603.236%201.169.66%201.603.421.433.975.672%201.566.672.582%200%201.152-.24%201.588-.679.417-.418.645-.97.645-1.596%200-.615-.228-1.182-.645-1.608zm.176-.177c.464.477.713%201.108.713%201.785%200%20.696-.249%201.305-.713%201.771a2.469%202.469%200%200%201-1.763.758c-.66%200-1.27-.266-1.74-.748a2.517%202.517%200%200%201-.73-1.78c0-.666.257-1.302.736-1.798a2.365%202.365%200%200%201%201.734-.73c.673%200%201.29.263%201.763.742z'/%3e%3c/g%3e%3c/svg%3e)
'%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpolyline%20id='Fill-1'%20class='st0'%20points='0.1,56.1%200.2,148.5%2017.7,148.5%2017.7,56.1%200.1,56.1%20'/%3e%3cpolyline%20id='Fill-3'%20class='st1'%20points='46.9,0.9%2046.9,148.5%2064.6,148.5%2064.6,0.9%2046.9,0.9%20'/%3e%3cpolygon%20id='Fill-4'%20class='st1'%20points='94.7,148.5%20112.4,148.5%20112.4,0.9%2094.7,0.9%20'/%3e%3cpath%20id='Fill-5'%20class='st1'%20d='M219.3,148.5h-17.6v-14.2h-0.4c-10.9,23.8-64,25.9-64-18.7l-0.1-59.5h17.6v54.6%20c0,17.4,10,23.8,21.1,23.8c14.6,0,25.8-9.4,25.7-30.8V56.1h17.6L219.3,148.5'/%3e%3c/g%3e%3cpath%20id='Fill-7'%20class='st1'%20d='M244.9,56.1h16.4v14.4h0.4c1.8-5.5,13.1-16.8,29.7-16.8c13.7,0,23,5.9,28.9,17.2%20c6.1-11.3,18.2-17.2,29.3-17.2c28.5,0,35.1,20.3,35.2,41v53.9h-17.6V97.1c0-14.1-3-26.9-19.9-26.9c-17,0-23.6,11.5-23.6,27.9v50.5%20H306v-48.4c0-17.6-2.6-30-19.5-30c-12.7,0-24,9.6-24,30.4v48h-17.6V56.1'/%3e%3cpolygon%20id='Fill-8'%20class='st1'%20points='408.6,148.5%20426.2,148.5%20426.2,56.1%20408.6,56.1%20'/%3e%3cpath%20id='Fill-9'%20class='st1'%20d='M452.1,56.1h17.6v14.2h0.4c10.9-23.8,64-25.9,64,18.7v59.5h-17.6V93.9c0-17.4-10-23.8-21.1-23.8%20c-14.6,0-25.8,9.4-25.7,30.8v47.6h-17.6L452.1,56.1'/%3e%3cg%20id='Group-13'%20transform='translate(0.000000,%2012.000000)'%3e%3cg%20id='Clip-11'%3e%3c/g%3e%3cpath%20id='Fill-10'%20class='st1'%20d='M567.6,66.3c6.4-4.9,12.9-10.5,26.3-10.5c15,0,22.1,9.9,22.1,19.5v3.9c-17.6,0-63.8-2.5-63.8,32%20c0,18,14.8,27.7,32,27.7c14,0,24.6-4.5,32.4-16.4h0.4c0,4.7,0.2,9.4,0.6,14.1h15.6c-1.3-10.7-0.8-65-0.8-64%20c0-35.6-51.9-39.2-75.3-17.2L567.6,66.3z%20M616.1,92.1V98c0,12.5-6.8,26.9-26.3,26.9c-12.1,0-19.9-4.5-19.9-15%20C569.8,91.3,600.3,92.1,616.1,92.1L616.1,92.1z'/%3e%3cpath%20id='Fill-12'%20class='st0'%20d='M11.8,0C5.3,0,0,5.3,0,11.8s5.3,11.8,11.8,11.8s11.8-5.3,11.8-11.8S18.3,0,11.8,0'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
FY2024 (Dec) proxy
- AddedBioMarinpay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- AddedSareptapay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- AddedUnited Therapeuticspay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- RemovedAbiomedpay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- RemovedCareDXpay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- RemovedGlaukospay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- RemovedNevropay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- RemovedPenumbrapay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
- RemovedVeracytepay peer groupSpecifically, the committee removed Abiomed (acquired), CareDX, Glaukos, Nevro, Penumbra, and Veracyte, which no longer met the criteria, and added BioMarin, Sarepta and United Therapeutics
FY2023 (Dec) proxy
- AddedIonis Pharmaceuticalspay peer group
- AddedMyriad Geneticspay peer group
- AddedNeurocrine Biosciencespay peer group
- AddedUltragenyx Pharmaceuticalpay peer group
- RemovedInsuletpay peer group
- RemovedInvitaepay peer group
- RemovedLuminexpay peer group
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.